Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Antagonist Clear all
Recruiting Phase 2Phase 3 Interventional

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673
View directory record Official record
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
47
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

NCT04849559
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Results available

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

NCT02100228
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

NCT01630590
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabozantinib, Androgen Ablation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Results available

PROMUS Element Plus US Post-Approval Study

NCT01589978
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 21, 2026, 6:21 PM EDT
Withdrawn No phase listed Observational

Visceral Afferents

NCT04794335
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Male Hormonal Contraceptive Development-ACY-5

NCT00161447
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders

NCT02322047
View directory record Official record
Conditions
Alcohol Use Disorder, Posttraumatic Stress Disorder (PTSD)
Interventions
Prazosin, Naltrexone, Placebo (Prazosin), Placebo (Naltrexone)
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 21, 2026, 6:21 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 21, 2026, 6:21 PM EDT
Active, not recruiting Phase 1 Interventional

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

NCT00878163
View directory record Official record
Conditions
Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Diagnostic Laboratory Biomarker Analysis, Erlotinib Hydrochloride, Gemcitabine Hydrochloride, Vismodegib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

NCT00098293
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01316887
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719, Placebo once-daily
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 120 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Mobile, Alabama • Sunset, Louisiana • Plymouth, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene

NCT00072111
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
anakinra
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 21, 2026, 6:21 PM EDT
Recruiting Phase 4 Interventional

Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

NCT07174349
View directory record Official record
Conditions
Urinary Retention Postoperative
Interventions
Uroselective alpha-1-adrenergic receptor antagonist, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 21, 2026, 6:21 PM EDT
Terminated Phase 1 Interventional

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

NCT03277209
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Plerixafor
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 21, 2026, 6:21 PM EDT
Recruiting Phase 1 Interventional

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267
View directory record Official record
Conditions
Breast Cancer, Advanced Solid Tumor
Interventions
BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

NCT02484456
View directory record Official record
Conditions
Major Depression
Interventions
AV 101 (4-Chlorokynurenine), Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 2 Interventional

Treatment of Parkinson's Disease With Eliprodil

NCT00001929
View directory record Official record
Conditions
Movement Disorders, Parkinson Disease
Interventions
Eliprodil
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females

NCT00651534
View directory record Official record
Conditions
Osteoporosis
Interventions
Ronacaleret
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Analyzing Female Trauma Exposed Responses to a Medication

NCT01814332
View directory record Official record
Conditions
Stress Disorders, Post-traumatic
Interventions
GSK561679, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 21, 2026, 6:21 PM EDT
Completed Early Phase 1 Interventional

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
Interventions
Biopsy, Daratumumab, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
Procedure · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 21, 2026, 6:21 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

NCT05217498
View directory record Official record
Conditions
Spinal Cord Injuries, Myelopathy
Interventions
Istradefylline, low oxygen therapy
Drug · Device
Lead sponsor
Randy Trumbower, PT, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 21, 2026, 6:21 PM EDT
Completed No phase listed Observational Results available

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 21, 2026, 6:21 PM EDT